Role of Tregs in Cancer Dormancy or Recurrence

Immunol Invest. 2016 Nov;45(8):759-766. doi: 10.1080/08820139.2016.1194428. Epub 2016 Sep 7.

Abstract

The immunogenic tumor dormancy has been demonstrated in animal models of cancer, which can explain clinical observations such as an increased incidence of cancer following organ transplantation. The role of immune cell populations in the maintenance of, or escape from, tumor dormancy and subsequent recurrence is poorly understood. Here, we provide a review of literature related to the contribution of Tregs in tumor dormancy or recurrence. Based on clinical results, we suggest that anecdotal reports on the association of human Tregs with poor prognosis are circumstantial rather than implying a cause-effect direction. This could be due to a disparity among patients in harboring multiple factors associated with tumor immunoediting and immune evasion mechanisms.

Keywords: Regulatory T cells; tumor dormancy; tumor immunoediting.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Cytokines / genetics
  • Cytokines / immunology
  • Disease Models, Animal
  • Forkhead Transcription Factors / genetics
  • Forkhead Transcription Factors / immunology
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Immune Tolerance
  • Ki-67 Antigen / genetics
  • Ki-67 Antigen / immunology
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / immunology*
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / pathology
  • Neoplasms / drug therapy
  • Neoplasms / immunology*
  • Neoplasms / mortality
  • Neoplasms / pathology
  • Neoplastic Cells, Circulating / immunology
  • Neoplastic Cells, Circulating / pathology
  • Signal Transduction
  • Survival Analysis
  • T-Lymphocyte Subsets / immunology*
  • T-Lymphocyte Subsets / pathology
  • Tumor Escape*

Substances

  • Antineoplastic Agents
  • Cytokines
  • FOXP3 protein, human
  • Forkhead Transcription Factors
  • Ki-67 Antigen